|
1 Indications And Usage Phesgo Is A Combination Of Pertuzumab And Trastuzumab, Her2/neu Receptor Antagonists, And Hyaluronidase, An Endoglycosidase, Indicated For: Use In Combination With Chemotherapy As: Neoadjuvant Treatment Of Patients With Her2-Positive, Locally Advanced, Inflammatory, Or Early Stage Breast Cancer (Either Greater Than 2 Cm In Diameter Or Node Positive) As Part Of A Complete Treatment Regimen For Early Breast Cancer. ( 1.1 ) Adjuvant Treatment Of Patients With Her2-Positive Early Breast Cancer At High Risk Of Recurrence ( 1.1 ) Use In Combination With Docetaxel For Treatment Of Patients With Her2-Positive Metastatic Breast Cancer (Mbc) Who Have Not Received Prior Anti-Her2 Therapy Or Chemotherapy For Metastatic Disease. ( 1.2 ) 1.1 Early Breast Cancer (Ebc) Phesgo Is Indicated For Use In Combination With Chemotherapy For The Neoadjuvant Treatment Of Adult Patients With Her2-Positive, Locally Advanced, Inflammatory, Or Early Stage Breast Cancer (Either Greater Than 2 Cm In Diameter Or Node Positive) As Part Of A Complete Treatment Regimen For Early Breast Cancer [See Dosage And Administration (2.2) And Clinical Studies (14.2) ] . The Adjuvant Treatment Of Adult Patients With Her2-Positive Early Breast Cancer At High Risk Of Recurrence [See Dosage And Administration (2.2) And Clinical Studies (14.2) ] . Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic Test [See Dosage And Administration (2.1) ]. 1.2 Metastatic Breast Cancer (Mbc) Phesgo Is Indicated For Use In Combination With Docetaxel For The Treatment Of Adult Patients With Her2-Positive Metastatic Breast Cancer Who Have Not Received Prior Anti-Her2 Therapy Or Chemotherapy For Metastatic Disease [See Dosage And Administration (2.2) And Clinical Studies (14.1) ] . Select Patients For Therapy Based On An Fda-Approved Companion Diagnostic Test [See Dosage And Administration (2.1) ].
|